Everything You Need To Know About These Three Hot Biotech Stocks
July 29 2016 - 8:05AM
InvestorsHub NewsWire
Unilife Corporation (NASDAQ:
UNIS) is a developer and commercial supplier of
injectable drug delivery systems. UNIS has a portfolio of
innovative, differentiated products with a primary focus on
wearable injectors. UNIS shares fell to $2.64 on May 24, 2016 but
have rebounded to over $4 per share. The company has been beseeched
by several law firms seeking class action shareholder lawsuits. The
report that follows will update you completely about UNIS- Read More
The acquisition of BioD, LLC, a private company, has been announced
by Derma Sciences Inc. (NASDAQ:
DSCI) a tissue regeneration company focused on
advanced wound and burn care. It offers a line of products with
patented technologies to help better manage chronic and
hard-to-heal wounds, many of which result from diabetes and poor
vascular functioning. The report that follows will give you details
of the transaction and describes the synergies created by the
combination- Read More
Evoke Pharma, Inc. (NASDAQ:
EVOK) is a specialty pharmaceutical company focused
primarily on the development of drugs to treat GI disorders and
diseases. EVOK shares tumbled 85% earlier this month when the
company’s Phase III clinical trial of EVK-001 failed to achieve its
primary endpoint of symptom improvement at the end of four weeks in
female patients with symptomatic diabetic gastroparesis. Find out
if this is the end for EVOK and EVK-001 when you read this article-
Read More
DISCLAIMER
FORWARD-LOOKING
DISCLAIMER
This press release may contain
certain forward-looking statements and information, as defined
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and is subject
to the Safe Harbor created by those sections. This material
contains statements about expected future events and/or financial
results that are forward-looking in nature and subject to risks and
uncertainties. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance or achievements of the subject company
in this report to be materially different from the statements made
herein.
COMPLIANCE PROCEDURE
Content is researched, written and
reviewed on a best-effort basis. Information in this release is
fact checked and produced on a best efforts basis. However, we are
only human and are prone to make mistakes. If you notice any errors
or omissions, please notify us below. The subject Companies have
not compensated Traders News Source for the creation or
dissemination of this report. Traders News Source is the party
responsible for issuing this report/release and for hosting the
full report on Traders News Source website.
NOT FINANCIAL ADVICE
Traders News Source makes no
warranty, expressed or implied, as to the accuracy or completeness
or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to
be construed as personal financial advice. Readers are encouraged
to consult their personal financial advisor before making any
decisions to buy, sell or hold any securities mentioned
herein.
NO WARRANTY OR LIABILITY
ASSUMED
Traders News Source is not
responsible for any error which may be occasioned at the time of
printing of this document or any error, mistake or shortcoming. No
liability is accepted by Traders News Source whatsoever for any
direct, indirect or consequential loss arising from the use of this
document. Traders News Source expressly disclaims any fiduciary
responsibility or liability for any consequences, financial or
otherwise arising from any reliance placed on the information in
this document. Traders News Source does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
Traders News Source produces
reports, articles, blogs, and investment newsletters covering
companies listed on NYSE and NASDAQ exchanges. Traders News Source
has two distinct and independent operating segments. One produces
non-compensated analyst and or expert certified content generally
in the form of press releases, articles and reports. The other
produces compensated content, which typically consists of
compensated investment newsletters, articles and
reports.
HIGH DEGREE OF RISK
There is an extremely high inherent
risk when investing in micro and small cap biotech securities
that
have little to no revenue and are
dependent upon an approval from the development of their
drug
pipeline. You could lose your entire
investment.
Source: Traders News
Source
Contact:
editor@tradersnewssource.com